LYVE1 Antikörper

Produktnummer ABIN1589906

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch LYVE1 in WB, IHC (p), IF und IHC (fro). Es zeigt Reaktivität gegenüber Proben von Human. Es wurde in 4+ Publikationen zitiert.

Kurzübersicht für LYVE1 Antikörper (ABIN1589906)

Target: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LYVE1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Produktdetails anti-LYVE1 Antikörper

Verwendungszweck: Rabbit Anti-Human Lyve-1 Polyclonal Antibody

Spezifität: Recombinant human LYVE-1

Produktmerkmale: Chromosomal location: 11p15
Produced from sera of rabbits immunized with highly pure recombinant human soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

Aufreinigung: Protein-A purified

Immunogen: Recombinant human LYVE-1 (ABIN1589751)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western Blot: Use 1-5 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handhabung: Centrifuge vial prior to opening.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Referenzen für anti-LYVE1 Antikörper (ABIN1589906)

Matsusaki, Fujimoto, Shirakata, Hirakawa, Hashimoto, Akashi: "Development of full-thickness human skin equivalents with blood and lymph-like capillary networks by cell coating technology." in: Journal of biomedical materials research. Part A, (2015) (PubMed).

Roost, van Iperen, de Melo Bernardo, Mummery, Carlotti, de Koning, Chuva de Sousa Lopes: "Lymphangiogenesis and angiogenesis during human fetal pancreas development." in: Vascular cell, Vol. 6, pp. 22, (2015) (PubMed).

Rohringer, Holnthoner, Hackl, Weihs, Rünzler, Skalicky, Karbiener, Scheideler, Pröll, Gabriel, Schweighofer, Gröger, Spittler, Grillari, Redl: "Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells." in: PLoS ONE, Vol. 9, Issue 12, pp. e114806, (2014) (PubMed).

Kawai, Kaidoh, Yokoyama, Ohhashi: "Pivotal roles of lymphatic endothelial cell layers in the permeability to hydrophilic substances through collecting lymph vessel walls: effects of inflammatory cytokines." in: Lymphatic research and biology, Vol. 12, Issue 3, pp. 124-35, (2014) (PubMed).

Details zu LYVE1

Target: LYVE1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1))

Andere Bezeichnung: Lyve-1

Hintergrund:

Synonyms: LYVE1, HAR, XLKD1, LYVE-1, CRSBP-1

Description: LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41 % similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 Molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 Molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

Gen-ID: 10894

NCBI Accession: NM_006691, NP_006682

UniProt: Q9Y5Y7

Pathways: Glycosaminoglycan Metabolic Process